Effective treatment against COVID19
- About us
- What We Do
- Medical Services
- Blogs
- Biologics : The Race horses
- Biologics : The work horses
- Biologics : Hidden Gems
- Biosimilars : 2024 a Defining year for Biosimilars
- Complexities of Healthcare
- New Drug Launches
- Rise of Cancer
- Cancer Trends in GenX
- Breast Cancer: Understanding the Risk
- The Race to Reinvent Weight Loss
- How ChatGPT is Revolutionizing Cancer Care Conversations
- India’s Pharma Titans
- Rethinking Supply Chains in the Pharmaceutical Industry
- Case Studies
- Overview
- Contact Us
Overview
COVID 19 was a global crisis unlike any seen in modern times. The virus created havoc across the entire world with healthcare responders struggling to find the right treatment owing to the novel nature of the virus. There was a need for identifying and developing an effetive treatment for the management of the disease.
The following case study for an Indian Pharma company captures Creating a swift and strategic response to an unprecedented global crisis: introducing Favipiravir within just three months of India’s lockdown, combating COVID-19 head-on.
Introduction
The COVID-19 pandemic posed an unprecedented challenge to healthcare systems worldwide. The urgent need for effective treatments led to a global race to identify and develop drugs that could combat the virus and mitigate its impact on patients. This case study by Atticus Healthcare highlights the strategic approach taken to identify and launch an effective treatment for COVID-19 in India, with a focus on the antiviral drug Favipiravir.
Problem Statement
The primary challenge was to determine the most effective and impactful treatment to combat the COVID-19 virus. Given the rapidly evolving nature of the pandemic and the urgent need for effective therapeutic options, the goal was to identify a treatment that could be quickly brought to market to help manage the disease and reduce its severity.
Approach and Methodology
-
Continuous Monitoring and Deliberations
Monitoring the Virus:
- Continuous surveillance of the novel SARS-CoV-2 virus through government portals.
- Regular discussions with treating physicians, pulmonologists, and intensivists who were on the front lines managing COVID-19 patients.
Physician Insights:
- Engaged in multiple deliberations with leading physicians in India to understand their experiences and insights into managing the disease.
- Favipiravir was shortlisted based on its potential efficacy and the feedback from healthcare professionals.
-
Exhaustive Evaluation of Antivirals
Effectiveness Across Viruses:
- Conducted an exhaustive evaluation of existing antiviral drugs concerning their effectiveness against viruses from different morphologic families.
Mechanism of Action:
- Critically appraised data on Favipiravir’s effectiveness against other viruses like Influenza.
- Evaluated the mechanism of action of Favipiravir in inhibiting viral genome replication, which was crucial for its potential use against SARS-CoV-2.
-
Real-Time Disease Management
Global Context Monitoring:
- Monitored the real-time management of COVID-19 in both Indian and global contexts to understand treatment outcomes and strategies.
Dynamic Forecasting:
- Undertook dynamic global forecasting of the disease’s progression to anticipate the benefits and course of Favipiravir therapy.
-
Regulatory Approval
Regulatory Engagement:
- Compiled and presented data to Indian drug regulators demonstrating Favipiravir’s potential effectiveness against COVID-19.
- Successfully obtained approval to market Favipiravir for COVID-19 treatment in India.
Outcomes and Results
Rapid Launch
- Record Time to Market:
- Launched Favipiravir within a record time of three months following the announcement of the lockdown in India.
- Demonstrated the capability to rapidly respond to the urgent healthcare crisis with an effective treatment option.
Real-World Evidence
- Clinical Effectiveness:
- Favipiravir showed real-world evidence in reducing hospital stay duration.
- Played a significant role in preventing the worsening of the disease in patients with mild to moderate COVID-19, thereby reducing the strain on healthcare facilities.
Conclusion
The rapid identification, evaluation, and launch of Favipiravir as a treatment for COVID-19 in India underscores the importance of strategic planning, continuous monitoring, and collaboration with healthcare professionals. This case study by Atticus Healthcare highlights the successful implementation of a treatment strategy that not only met the urgent needs of the pandemic but also provided a robust framework for future healthcare challenges.
Make An Appointment Today
We have an excellent team to give you the best service of caregiving and take care of your loved ones. If you want to explore more about us and give us a chance to get you our finest service, book an appointment today and become a part of our community.